Here is the list of references for the information provided in this site:

  1. Astarita, G. et al. 2010. Deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in Alzheimer’s disease. PLoS One. 5(9): e12538.
  2. Bateman, R. J. et al. 2012. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N. Engl. J. Med. 367(9): 795-804.
  3.  Shie, F. S. et al. 2002. Diet-induced hypercholesterolemia enhances brain A beta accumulation in transgenic mice. Neuroreport. 13(4): 455–459.
  4.  Schedin, S. et al. 1997. Peroxisomal impairment in Niemann-Pick type C disease. J. Biol. Chem. 272(10): 6245-6251.
  5.  Refolo, L. M. et al. 2001. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer’s disease. Neurobiol. Dis. 8(5): 890–899.
  6.  Oma, S. et al. 2012. Changes in Phospholipid Composition of Erythrocyte Membrane in Alzheimer’s Disease. Dement. Geriatr. Cogn. Disord. Extra. 2(1): 298-303.
  7. Masataka, I. et al. 2012. Anti-inflammatory/anti-amyloidogenic effects of plasmalogens in lipopolysaccharide-induced neuroinflammation in adult mice. J. Neuroinflammation. 9: 197-209.
  8.  Kivipelto, M. et al. 2001. Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. BMJ. 322(7300): 1447–1451.
  9.  Katafuchi, T. et al. 2012. Effects of plasmalogens on systemic lipopolysaccharide-induced glial activation and β-amyloid accumulation in adult mice. Ann. N.Y. Acad. Sci. 1262: 85-92.
  10.  Hossain, M. S. et al. 2013. Plasmalogens rescue neuronal cell death through an activation of AKT and ERK survival signaling. PLoS One. 8(12): e83508.
  11. Hiratsuka, S. et al. 2009. Effects of dietary docosahexaenoic acid connecting phospholipids on the learning ability and fatty acid composition of the brain. J. Nutr. Sci. Vitaminol. 55(4): 374-380.
  12.  Han, X. et al. 2001. Plasmalogen deficiency in early Alzheimer’s disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. J. Neurochem. 77(4): 1168–1180.
  13.  Guan, Z. et al. 1999. Decrease and structural modifications of phosphatidylethanolamine plasmalogen in the brain with Alzheimer disease. J. Neuropathol. Exp. Neurol. 58(7): 740–747.
  14.  Goodenowe, D. B. et al. 2015. Relation of plasmalogens, ApoE genotype, and Alzheimer’s disease pathology to cognition: A post-mortem analysis. Alzheimer’s & Dementia. 11(7) Supplement: 865-866.
  15.  Goodenowe, D. B. et al. 2014. Relation of plasmalogen biosynthesis to cognition and AD in older persons. Alzheimer’s & Dementia. 10(4) Supplement: 887.
  16.  Goodenowe, D. B. et al. 2007. Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer’s disease and dementia. J. Lipid Res. 48(11): 2485–2498.
  17.  Ginsberg, L. et al. 1998. Membrane instability, plasmalogen content, and Alzheimer’s disease. J. Neurochem. 70 (6): 2533–2538.
  18.  Ginsberg, L. et al. 1995. Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer’s disease brain. Brain Res. 698(1-2): 223–226.
  19.  Folstein, M. F. et al. 1975. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician.  J. Psychiatr. Res. 12(3): 189-198.
  20.  Farooqui, A. A. & Horrocks, L. A. 2001. Plasmalogens: workhorse lipids of membranes in normal and injured neurons and glia. Neuroscientist. 7(3): 232-245.
  21.  Faison, W. E. 2005. Formulating a clinical practice care plan for the diagnosis and assessment of Alzheimer’s disease. CNS Spectr. 10(11 Suppl 18): 10-12.
  22.  Fabelo, N. et al. 2011. Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson’s disease and incidental Parkinson’s disease. Mol. Med. 17(9-10): 1107-1118.
  23. Corder, E. H. et al. 1993. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science. 261(5123): 921–923.
  24. Conquer, J. A. et al. 2000. Fatty acid analysis of blood plasma of patients with Alzheimer’s disease, other types of dementia, and cognitive impairment. Lipids. 35(12): 1305–1312.
  25. Brosche, T. 1997. Plasmalogen phospholipids – facts and theses to their antioxidative qualities. Arch. Gerontol. Geriatr. 25(1): 73-81.
  26. Braverman, N. E. & Moser, A. B. 2012. Functions of plasmalogen lipids in health and disease. Biochim. Biophys. Acta. 1822(9): 1442-1452.
  27. Borson, S. et al. 2003. The Mini-Cog as a screen for dementia: validation in a population-based sample. J. Am. Geriatr. Soc. 51(10): 1451-1454.
  28.  Borson, S. et al. 2000. The mini-cog: a cognitive “vital signs” measure for dementia screening in multi-lingual elderly. Int. J. Geriatr. Psychiatry. 15(11): 1021-1027.
  29. Borson, S. et al. 2006. Improving identification of cognitive impairment in primary care. Int. J. Geriatr. Psychiatry. 21(4): 349-355.
  30. Mawatari, S. et al., 2007. Separation of intact plasmalogens and all other phospholipids by a single run of high-performance liquid chromatography. Analytical Biochemistry. 370(1): 54-59.
  31. Mawatari, S. et al. 2009. Simultaneous preparation of purified plasmalogens and sphingomyelin in human erythrocytes with phospholipase A1 from Aspergillus orizae. Biosci. Biotechnol. Biochem. 73(12): 2621-2625.
  32.  Mawatari S. et al. 2012. Dietary plasmalogen increases erythrocyte membrane plasmalogen in rats. Lipids Health Dis. 11: 161-167.
  33.  Murphy, E. J. et al. 2000. Phospholipid composition and levels are altered in Down syndrome brain. Brain Res. 867(1-2): 9-18.
  34. Wood, P. L. et al. 2010. Circulating plasmalogen levels and Alzheimer Disease Assessment Scale–Cognitive scores in Alzheimer patients. J. Psychiatry Neurosci. 35(1): 59-62.
  35.  Wood, P. L. et al. 2011. Plasmalogen Deficit: A New and Testable Hypothesis for the Etiology of Alzheimer’s Disease, Alzheimer’s Disease Pathogenesis-Core Concepts, Shifting Paradigms and Therapeutic Targets, Dr. Suzanne De La Monte (Ed.), InTech, DOI: 10.5772/17630.
  36. Gugała, M. et al. 2007. Przegląd metod neuropsychologicznych służących do diagnozy łagodnych zaburzeń poznaw­czych. Post. Psychiatr. Neurol. 16(1): 81–85.
  37. Szcześniak, D. & Rymaszewska, J. 2015. The usefulness of the SLUMS test for diagnosis of mild cognitive impairment and dementia. Psychiatr. Pol. ONLINE FIRST Nr 18.
  38. Nasreddine, Z. S. et al. 2005. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J. Am. Geriatr. Soc. 53(4): 695-699.
  39. Bichenkov E, Ellingson JS. 1999. Temporal and quantitative expression of the myelin-associated lipids, ethanolamine plasmalogen, galactocerebroside, and sulfatide, in the differentiating CG-4 glial cell line. Neurochem. Res. 24(12): 1549–1556.
  40. Brites, P et al. 2009. Plasmalogens participate in very-long-chain fatty acid-induced pathology. Brain. 132(Pt 2): 482–492.
  41. Buddecke, E. & Andresen, G. 1959. Quantitative Bestimmung der Acetalphosphatide (Plasmalogene) in der Aorta des Menschen unter Berucksichtigung der Arteriosklerose. Hoppe-Seyler’s Z. Physiol. Chem. 314: 38–45.
  42. Colas, R. et al. 2011. LDL from obese patients with themetabolic syndrome show increased lipid peroxidation and activate platelets. Diabetologia 54(11): 2931–2940.
  43. Demediuk, P. et al. 1985. Membrane lipid changes in laminectomized and traumatized cat spinal cord. Proc. Natl. Acad. Sci. U. S. A. 82(20): 7071–7075.
  44. Hazen, S. L. et al. 1991. Activation of a membrane-associated phospholipase A2 during rabbit myocardial ischemia which is highly selective for plasmalogen substrate. J. Biol. Chem. 266(9): 5629–5633.
  45. Hofteig, J. H. et al. 1985. Synaptic membrane phospholipids: effects of maternal ethanol consumption. Exp. Neurol. 87(1): 165–171.
  46. Khan, M et al. 2008. Plasmalogen deficiency in cerebral adrenoleukodystrophy and its modulation by lovastatin. J. Neurochem. 106(4): 1766–1779.
  47. Lohner, K. et al. 1991. Stabilization of non-bilayer structures by the etherlipid ethanolamine plasmalogen. Biochim. Biophys. Acta. 1061(2):132–140.
  48. Mandel, H. et al. 1998. Plasmalogen phospholipids are involved in HDL-mediated cholesterol efflux: insights from investigations with plasmalogen-deficient cells. Biochem. Biophys. Res. Commun. 250(2):369–373.
  49. Martínez, M. et al. 2000. Therapeutic effects of docosahexaenoic acid ethyl ester in patients with generalized peroxisomal disorders. Am. J. Clin. Nutr. 71(1 Suppl): 376S–385S.
  50. Portilla, D. et al. 1994. Role of cytosolic calcium-independent plasmalogen-selective phospholipase A2 in hypoxic injury to rabbit proximal tubules. J. Clin. Invest. 93(4): 1609–1615.
  51. Reddy, T. S. et al. 1982. Effects of nutritional rehabilitation on the content and lipid composition of brain gray and white matter of neonatally undernourished rats. J. Neurochem. 39(5): 1297–1301.
  52. Rudiger, M et al. 1998. Plasmalogens effectively reduce the surface tension of surfactant-like phospholipid mixtures. Am. J. Physiol. 274(1 Pt 1): L143–L148.
  53. Rudiger, M. et al. 2000. Preterm infants with high polyunsaturated fatty acid and plasmalogen content in tracheal aspirates develop bronchopulmonary dysplasia less often. Crit. Care Med. 28(5): 1572–1577.
  54. Rudiger, M. et al. 2005. Naturally derived commercial surfactants differ in composition of surfactant lipids and in surface viscosity. Am. J. Physiol. Lung Cell. Mol. Physiol. 288(2): L379–L383.
  55. Shoemaker, W. J. & Bloom, F. E. 1977. Effect of undernutrition on brain morphology. In: Wurtman RJ, Wurtman JJ, editors. Nutrition and the brain. New York: Raven. p 147–92.
  56. Singh, I. et al. 2004. Impaired peroxisomal function in the central nervous system with inflammatory disease of experimental autoimmune encephalomyelitis animals and protection by lovastatin treatment. Brain Res. 1022(1-2): 1–11.
  57. Wang-Sattler, R. et al. 2008. Metabolic profiling reveals distinct variations linked to nicotine consumption in humans—first results from the KORA study. PLoS One. 3(12): e3863.
  58. Wing, D. R. et al. 1982. Effects of chronic ethanol administration on the composition of membrane lipids in the mouse. Biochem. Pharmacol. 31(21): 3431–3439.
  59. Wykle, R. L. & Schremmer Lockmiller, J. M. 1975. The biosynthesis of plasmalogens by rat brain: involvement of the microsomal electron transport system. Biochim. Biophys. Acta. 380(2):291–298.
  60. Yamashita, S. et al. 2016. Analysis of Plasmalogen Species in Foodstuffs. Lipids. 51(2): 199-210.
  61. Zoeller, R. A. et al. 1988. A possible role for plasmalogens in protecting animal cells against photosensitized killing. J. Biol. Chem. 263(23): 11590–11596.
  62. Zoeller, R. A. et al. 1999. Plasmalogens as endogenous antioxidants: somatic cell mutants reveal the importance of the vinyl ether. Biochem. J. 338 (Pt. 3): 769–776.
  63. Zoeller, R. A. et al. 2002. Increasing plasmalogen levels protects human endothelial cells during hypoxia. Am. J. Physiol. Heart Circ. Physiol. 283(2): H671–H679.